Merck Millipore Adds Protein PEGylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH

Merck Millipore, the Life Science business of Merck, and celares GmbH today announced a collaboration with celares GmbH to provide PEGylation services to customers developing protein-based therapeutics and biosimilars.

The new service offering enabled by the collaboration includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale.